Comparative Pharmacology
Head-to-head clinical analysis: DYLOJECT versus IBUPROFEN AND PHENYLEPHRINE HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DYLOJECT versus IBUPROFEN AND PHENYLEPHRINE HYDROCHLORIDE.
DYLOJECT vs IBUPROFEN AND PHENYLEPHRINE HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2), thereby reducing prostaglandin synthesis, which mediates inflammation, pain, and fever.
Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis. Phenylephrine is a selective alpha-1 adrenergic receptor agonist, causing vasoconstriction.
50 mg intramuscularly every 6 hours as needed for pain; maximum 150 mg per day.
1 tablet (ibuprofen 200 mg/phenylephrine HCl 10 mg) orally every 4-6 hours as needed, not to exceed 6 tablets per 24 hours.
None Documented
None Documented
2-4 hours (terminal) in adults; prolonged in elderly (up to 6-8 hours) and hepatic impairment (up to 12 hours).
Ibuprofen: 2-4 hours (prolonged in overdose or hepatic impairment). Phenylephrine: 2-3 hours (clinical activity may persist longer due to vasoconstrictive effects).
Renal: ~50% as unchanged drug and metabolites (glucuronide conjugates); Biliary/fecal: ~40% as metabolites; <5% unchanged in feces.
Ibuprofen: Renal elimination of metabolites (90%) and unchanged drug (1-10%); biliary/fecal excretion minor. Phenylephrine: Renal elimination (80-85% as inactive metabolites, 2-3% unchanged); biliary/fecal negligible.
Category C
Category D/X
NSAID
NSAID